中轴型脊柱关节炎中多次治疗转换的发生情况:来自五个北欧风湿病注册中心的结果
基于丹麦、瑞典、芬兰、挪威和冰岛五个生物制剂注册中心的观察性队列研究,纳入2009至2018年首次启用生物制剂或靶向合成DMARD的8398例中轴型脊柱关节炎患者。结果显示,2009至2015年启动治疗的患者中,3年随访内使用≥3、≥4、≥5种b/tsDMARD者分别占8%、3%、1%;多药转换的累积发生率无日历时期趋势。与多药转换相关的基线特征包括女性、较短病程、较高患者总体评分、合并症及银屑病,但葡萄膜炎不在其列。
要点
- 8398例中轴型脊柱关节炎患者中,3年随访内使用≥3种b/tsDMARD者占8%,≥4种者占3%,≥5种者占1%。
- 多药转换的累积发生率在不同日历时期(2009-2011、2012-2013、2014-2015、2016-2018)之间无变化趋势。
- 多药转换(≥3种b/tsDMARD)的基线相关因素包括女性、较短病程、较高患者总体评分、合并症及银屑病,而非葡萄膜炎。
核心结论
- 在这一大型北欧中轴型脊柱关节炎观察性队列中,多次转换频繁发生,且未观察到明显的时间趋势。
- 临床相关因素包括性别,也包括既往合并症和关节外表现,凸显了治疗该患者群体持续存在的挑战。
研究设计与样本
- 观察性队列研究,基于五个生物制剂注册中心(丹麦、瑞典、芬兰、挪威、冰岛)2009至2018年首次启用b/tsDMARD的中轴型脊柱关节炎患者数据。
- 合并症和关节外表现通过链接国家注册中心识别。
- 多药转换按b/tsDMARD治疗史重叠分类定义:随访期间使用≥3、≥4或≥5种b/tsDMARD。
- 按日历时期(2009-2011、2012-2013、2014-2015、2016-2018)分层探索使用≥3种b/tsDMARD的多药转换累积发生率。
- 在2009至2015年首次启用b/tsDMARD的患者亚组中,采用多因素logistic回归分析探索与3年随访内多药转换相关的基线特征。
主要发现
- 共纳入8398例患者,其中6056例于2009至2015年首次启用b/tsDMARD(63%为男性,中位年龄42岁)。
- 在2009至2015年启动治疗的患者中,3年随访内使用≥3、≥4或≥5种b/tsDMARD的比例分别为8%、3%和1%。
- 日历时期不影响多药转换的累积发生率。
- 与多药转换(≥3种b/tsDMARD)相关的基线特征为女性、较短病程、较高患者总体评分、合并症及患有银屑病,但葡萄膜炎不在其列。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In axial spondyloarthritis (axSpA), switching between multiple biologic or targeted synthetic (b/ts-) DMARDs might indicate difficult-to-treat disease. We aimed to explore the occurrence of multiple switching in routine care axSpA patients using various definitions, and to identify associated clinical characteristics upon start of first b/tsDMARD (baseline). METHODS: Observational cohort study including patients with axSpA starting a first-ever b/tsDMARD 2009-2018 based on data from five biologic registries (Denmark/Sweden/Finland/Norway/Iceland). Comorbidities and extra-articular manifestations were identified through linkage to national registries. Multi-switching was defined in overlapping categories according to b/tsDMARD treatment history: treatment with ≥3, ≥4 or ≥5 b/tsDMARDs during follow-up. We explored the cumulative incidence of patients becoming multi-switchers with ≥3 b/tsDMARDs stratified by calendar-period (2009-2011, 2012-2013, 2014-2015, 2016-2018). In the subgroup of patients starting a first b/tsDMARD 2009-2015, baseline characteristics associated with multi-switching (within 3 years' follow-up) were explored using multiple logistic regression analyses. RESULTS: Among 8398 patients included, 6056 patients (63% male, median age 42 years) started a first b/tsDMARD in 2009-2015, whereof proportions treated with ≥3, ≥4 or ≥5 b/tsDMARDs within 3 years' follow-up were 8%, 3% and 1%, respectively. Calendar-period did not affect the cumulative incidence of multi-switching. Baseline characteristics associated with multi-switching (≥3 b/tsDMARDs) were female gender, shorter disease duration, higher patient global score, comorbidities and having psoriasis but not uveitis. CONCLUSION: In this large Nordic observational cohort of axSpA patients, multiple switching was frequent with no apparent time-trend. Clinical associated factors included gender, but also previous comorbidities and extra-articular manifestations illustrating the ongoing challenge of treating this patient group.
引用
- Di Giuseppe D, Lindström U, Aaltonen K, et al. The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. Rheumatology (Oxford). 2022. PMID: 34940795. doi:10.1093/rheumatology/keab946
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。